|Table of Contents|

Role for treatment of radiation and TKI in patients with leptomeningeal metastases from lung cancer：A Meta-analysis

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2019 05
Page:
791-796
Research Field:
Publishing date:

Info

Title:
Role for treatment of radiation and TKI in patients with leptomeningeal metastases from lung cancer：A Meta-analysis
Author(s):
Chen Zihao; Liu Tingting; Dang Jun
Department of Radiation Oncology，the First Hospital of China Medical University，Liaoning Shenyang 110001，China.
Keywords:
lung cancer; leptomeningeal metastases; radiation; tyrosine kinase inhibitor; Meta-analysis.
PACS:
R734.2
DOI:
10.3969/j.issn.1672-4992.2019.05.019
Abstract:
Objective：To determine whether treatment of radiation(RT) and tyrosine kinase inhibitor(TKI) improve survival compared with treatment of non-RT and non-TKI for patients with leptomeningeal metastases from lung cancer.Methods：The PubMed，EMBASE，Web of Science，and Cochrane Library were searched for articles which related to treatment of lung cancer with leptomeningeal metastases.The main outcome was overall survival(OS) and was compared by hazard ratios(HR).Statistical analysis was performed using the software Review Manager 5.3 and STATA MP14.0.Results：11 retrospective studies that included a total of 993 patients were eligible.RT significantly improved OS compared with non-RT treatment(HR：0.65，95%CI：0.52~0.81，P<0.001)，and TKI provided significant OS benefit compared with non-TKI treatment(HR：0.3，95%CI：0.24~0.38，P<0.001).Conclusion：Evidences from the current Meta-analysis suggested a potential OS benefit from RT and TKI treatment for patients with leptomeningeal metastases from lung cancer.Further prospective randomised controlled trials(RCT) are needed to confirm these findings.

References:

［1］Ferlay J，Shin HR，Bray F，et al.Estimates of worldwide burden of cancer in 2008：GLOBOCAN 2008［J］.Int J Cancer，2010，127(12)：2893-2917.
［2］Remon J，Le Rhun E，Besse B.Leptomeningeal carcinomatosis in non-small cell lung cancer patients：A continuing challenge in the personalized treatment era［J］.Cancer Treat Rev，2017，53：128-137.
［3］Le Rhun E，Galanis E.Leptomeningeal metastases of solid cancer［J］.Curr Opin Neurol，2016，29(6)：797-805.
［4］Umemura S，Tsubouchi K，Yoshioka H，et al.Clinical outcome in patients with leptomeningeal metastasis from non-small cell lung cancer：Okayama lung cancer study group［J］.Lung Cancer，2012，77(1)：134-139.
［5］Xu Q，Chen X，Qian D，et al.Treatment and prognostic analysis of patients with leptomeningeal metastases from non-small cell lung cancer［J］.Thorac Cancer，2015，6(4)：407-412.
［6］Park JH，Kim YJ，Lee JO，et al.Clinical outcomes of leptomeningeal metastasis in patients with non-small cell lung cancer in the modern chemotherapy era［J］.Lung Cancer，2012，76(3)：387-392.
［7］Lee SJ，Lee Ji，Nam Dh，et al.Leptomeningeal carcinomatosis in non-small cell lung cancer patients：Impact on survival and correlated prognostic factors［J］.J Thorac Oncol，2013，8(2)：185-191.
［8］Liao BC，Lee JH，Lin CC，et al.Epidermal growth factor receptor tyrosine kinase inhibitors for non-small cell lung cancer patients with leptomeningeal carcinomatosis［J］.J Thorac Oncol，2015，10(12)：1754-1761.
［9］Morris PG，Reiner AS，Szenberg OR，et al.Leptomeningeal metastasis from non-small cell lung cancer：Survival and the impact of whole brain radiotherapy［J］.J Thorac Oncol，2012，7(2)：382-385.
［10］Riess JW，Nagpal S，Iv M，et al.Prolonged survival of patients with non-small cell lung cancer with leptomeningeal carcinomatosis in the modern treatment era［J］.Clin Lung Cancer，2014，15(3)：202-206.
［11］Gong L，Xiong M，Huang Z，et al.Icotinib might be effective for the treatment of leptomeningeal carcinomatosis in non-small cell lung cancer with sensitive EGFR mutations［J］.Lung Cancer，2015，89(3)：268-273.
［12］Gwak HS，Joo J，Kim S，et al.Analysis of treatment outcomes of intraventricular chemotherapy in 105 patients for leptomeningeal carcinomatosis from non-small cell lung cancer［J］.J Thorac Oncol，2013，8(5)：599-605.
［13］Li YS，Jiang BY，Yang JJ，et al.Leptomeningeal metastases in patients with NSCLC with EGFR mutations［J］.J Thorac Oncol，2016，11(11)：1962-1969.
［14］Chuang TY，Yu CJ，Shih JY，et al.Cytologically proven meningeal carcinomatosis in patients with lung cancer：Clinical observation of 34 cases［J］.J Formos Med Assoc，2008，107(11)：851-856.
［15］Moher D，Liberati A，Tetzlaff J，et al.Preferred reporting items for systematic reviews and Meta-analyses：The PRISMA statement［J］.Int J Surg，2010，8(5)：336-341.
［16］Stang A.Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in Meta-analyses［J］.Eur J Epidemiol，2010 25(9)：603-605.
［17］Parmar MK，Torri V，Stewart L.Extracting summary statistics to perform Meta-analyses of the published literature for survival endpoints［J］.Stat Med，1998，17(24)：2815-2834.
［18］Tierney JF，Stewart LA，Ghersi D，et al.Practical methods for incorporating summary time-to-event data into Meta-analysis［J］.Trials，2007，8：16.
［19］Egger M，Davey Smith G，Schneider M，et al.Bias in Meta-analysis detected by a simple，graphical test［J］.BMJ，1997，315(7109)：629-634.
［20］Pan Z，Yang G，He H，et al.Concurrent radiotherapy and intrathecal methotrexate for treating leptomeningeal metastasis from solid tumors with adverse prognostic factors：A prospective and single-arm study［J］.Int J Cancer，2016，139(8)：1864-1872.
［21］Kuiper JL，Hendriks LE，Van der Wekken AJ，et al.Treatment and survival of patients with EGFR-mutated non-small cell lung cancer and leptomeningeal metastasis：A retrospective cohort analysis［J］.Lung Cancer，2015，89(3)：255-261.
［22］Yuan Y，Tan C，Li M，et al.Activity of pemetrexed and high-dose gefitinib in an EGFR-mutated lung adenocarcinoma with brain and leptomeningeal metastasis after response to gefitinib［J］.World J Surg Oncol，2012，10：235.
［23］Kuiper JL，Smit EF.High-dose，pulsatile erlotinib in two NSCLC patients with leptomeningeal metastases-one with a remarkable thoracic response as well［J］.Lung Cancer，2013，80(1)：102-105.
［24］Clarke JL，Pao W，Wu N，et al.High dose weekly erlotinib achieves therapeutic concentrations in CSF and is effective in leptomeningeal metastases from epidermal growth factor receptor mutant lung cancer［J］.J Neurooncol，2010，99(2)：283-286.
［25］Dhruva N，Socinski MA.Carcinomatous meningitis in non-small cell lung cancer：Response to high-dose erlotinib［J］.J Clin Oncol，2009，27(22)：e31-32.
［26］Lin CH，Lin MT，Kuo YW，et al.Afatinib combined with cetuximab for lung adenocarcinoma with leptomeningeal carcinomatosis［J］.Lung Cancer，2014，85(3)：479-480.
［27］Nanjo S，Ebi H，Arai S，et al.High efficacy of third generation EGFR inhibitor AZD9291 in a leptomeningeal carcinomatosis model with EGFR-mutant lung cancer cells［J］.Oncotarget，2016，7(4)：3847-3856.
［28］Nanjo S，Hata A，Okuda C，et al.Standard-dose osimertinib for refractory leptomeningeal metastases in T790M-positive EGFR-mutant non-small cell lung cancer［J］.Br J Cancer，2018，118(1)：32-37.（编校：文玉洁）

Memo

Memo:
辽宁省科学技术计划项目(编号：2012225016)
Last Update: 2019-02-01